Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/AKT2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/AKT2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/AKT2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/AKT2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/AKT2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/AKT2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/AKT2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0006091 | Colorectum | AD | generation of precursor metabolites and energy | 209/3918 | 490/18723 | 3.17e-28 | 6.61e-25 | 209 |
GO:0015980 | Colorectum | AD | energy derivation by oxidation of organic compounds | 143/3918 | 318/18723 | 2.78e-22 | 2.49e-19 | 143 |
GO:0072659 | Colorectum | AD | protein localization to plasma membrane | 122/3918 | 284/18723 | 2.86e-17 | 1.49e-14 | 122 |
GO:0009896 | Colorectum | AD | positive regulation of catabolic process | 180/3918 | 492/18723 | 4.33e-16 | 1.94e-13 | 180 |
GO:0031331 | Colorectum | AD | positive regulation of cellular catabolic process | 156/3918 | 427/18723 | 4.68e-14 | 1.05e-11 | 156 |
GO:1990778 | Colorectum | AD | protein localization to cell periphery | 129/3918 | 333/18723 | 5.51e-14 | 1.15e-11 | 129 |
GO:1903829 | Colorectum | AD | positive regulation of cellular protein localization | 110/3918 | 276/18723 | 4.58e-13 | 8.44e-11 | 110 |
GO:0090150 | Colorectum | AD | establishment of protein localization to membrane | 100/3918 | 260/18723 | 6.01e-11 | 6.33e-09 | 100 |
GO:0048732 | Colorectum | AD | gland development | 149/3918 | 436/18723 | 6.07e-11 | 6.33e-09 | 149 |
GO:1905475 | Colorectum | AD | regulation of protein localization to membrane | 73/3918 | 175/18723 | 3.37e-10 | 2.93e-08 | 73 |
GO:1904951 | Colorectum | AD | positive regulation of establishment of protein localization | 112/3918 | 319/18723 | 2.55e-09 | 1.80e-07 | 112 |
GO:0051222 | Colorectum | AD | positive regulation of protein transport | 106/3918 | 303/18723 | 8.45e-09 | 5.08e-07 | 106 |
GO:0006605 | Colorectum | AD | protein targeting | 105/3918 | 314/18723 | 1.39e-07 | 6.44e-06 | 105 |
GO:1905477 | Colorectum | AD | positive regulation of protein localization to membrane | 46/3918 | 106/18723 | 1.47e-07 | 6.64e-06 | 46 |
GO:0016050 | Colorectum | AD | vesicle organization | 101/3918 | 300/18723 | 1.65e-07 | 7.17e-06 | 101 |
GO:0090316 | Colorectum | AD | positive regulation of intracellular protein transport | 62/3918 | 160/18723 | 1.82e-07 | 7.79e-06 | 62 |
GO:0032388 | Colorectum | AD | positive regulation of intracellular transport | 74/3918 | 202/18723 | 1.83e-07 | 7.80e-06 | 74 |
GO:0032868 | Colorectum | AD | response to insulin | 91/3918 | 264/18723 | 2.02e-07 | 8.48e-06 | 91 |
GO:0032386 | Colorectum | AD | regulation of intracellular transport | 109/3918 | 337/18723 | 5.33e-07 | 1.95e-05 | 109 |
GO:0033157 | Colorectum | AD | regulation of intracellular protein transport | 80/3918 | 229/18723 | 5.81e-07 | 2.09e-05 | 80 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05235 | Oral cavity | OSCC | PD-L1 expression and PD-1 checkpoint pathway in cancer | 56/3704 | 89/8465 | 1.97e-04 | 6.55e-04 | 3.33e-04 | 56 |
hsa0466618 | Oral cavity | OSCC | Fc gamma R-mediated phagocytosis | 60/3704 | 97/8465 | 2.35e-04 | 7.72e-04 | 3.93e-04 | 60 |
hsa041504 | Oral cavity | OSCC | mTOR signaling pathway | 90/3704 | 156/8465 | 2.87e-04 | 9.15e-04 | 4.66e-04 | 90 |
hsa052236 | Oral cavity | OSCC | Non-small cell lung cancer | 46/3704 | 72/8465 | 4.37e-04 | 1.32e-03 | 6.72e-04 | 46 |
hsa041516 | Oral cavity | OSCC | PI3K-Akt signaling pathway | 185/3704 | 354/8465 | 6.26e-04 | 1.86e-03 | 9.49e-04 | 185 |
hsa041529 | Oral cavity | OSCC | AMPK signaling pathway | 71/3704 | 121/8465 | 6.29e-04 | 1.86e-03 | 9.49e-04 | 71 |
hsa0421110 | Oral cavity | OSCC | Longevity regulating pathway | 54/3704 | 89/8465 | 9.24e-04 | 2.65e-03 | 1.35e-03 | 54 |
hsa049267 | Oral cavity | OSCC | Relaxin signaling pathway | 74/3704 | 129/8465 | 1.20e-03 | 3.37e-03 | 1.72e-03 | 74 |
hsa052214 | Oral cavity | OSCC | Acute myeloid leukemia | 42/3704 | 67/8465 | 1.34e-03 | 3.75e-03 | 1.91e-03 | 42 |
hsa043806 | Oral cavity | OSCC | Osteoclast differentiation | 73/3704 | 128/8465 | 1.60e-03 | 4.44e-03 | 2.26e-03 | 73 |
hsa04370 | Oral cavity | OSCC | VEGF signaling pathway | 37/3704 | 59/8465 | 2.53e-03 | 6.62e-03 | 3.37e-03 | 37 |
hsa0421310 | Oral cavity | OSCC | Longevity regulating pathway - multiple species | 38/3704 | 62/8465 | 3.97e-03 | 9.86e-03 | 5.02e-03 | 38 |
hsa049365 | Oral cavity | OSCC | Alcoholic liver disease | 78/3704 | 142/8465 | 4.53e-03 | 1.12e-02 | 5.68e-03 | 78 |
hsa049317 | Oral cavity | OSCC | Insulin resistance | 60/3704 | 108/8465 | 8.66e-03 | 1.97e-02 | 1.00e-02 | 60 |
hsa04620 | Oral cavity | OSCC | Toll-like receptor signaling pathway | 58/3704 | 104/8465 | 8.77e-03 | 1.98e-02 | 1.01e-02 | 58 |
hsa04662 | Oral cavity | OSCC | B cell receptor signaling pathway | 48/3704 | 84/8465 | 9.02e-03 | 2.01e-02 | 1.03e-02 | 48 |
hsa0401518 | Oral cavity | OSCC | Rap1 signaling pathway | 107/3704 | 210/8465 | 2.01e-02 | 4.34e-02 | 2.21e-02 | 107 |
hsa04932112 | Oral cavity | OSCC | Non-alcoholic fatty liver disease | 124/3704 | 155/8465 | 1.22e-20 | 1.37e-18 | 6.96e-19 | 124 |
hsa05132114 | Oral cavity | OSCC | Salmonella infection | 174/3704 | 249/8465 | 2.67e-17 | 1.49e-15 | 7.58e-16 | 174 |
hsa05169113 | Oral cavity | OSCC | Epstein-Barr virus infection | 144/3704 | 202/8465 | 1.08e-15 | 3.60e-14 | 1.83e-14 | 144 |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
208 | AKT2 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR | inhibitor | CHEMBL2177390 | IPATASERTIB | |
208 | AKT2 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR | | GDC-0068 | IPATASERTIB | |
208 | AKT2 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR | allosteric modulator | 405560349 | | |
208 | AKT2 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR | | TRICIRIBINE | TRICIRIBINE | |
208 | AKT2 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR | inhibitor | 223366042 | CAPIVASERTIB | |
208 | AKT2 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR | inhibitor | CHEMBL3545134 | LY-2780301 | |
208 | AKT2 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR | inhibitor | 249565578 | IPATASERTIB | |
208 | AKT2 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR | | AFURESERTIB HYDROCHLORIDE | | |
208 | AKT2 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR | allosteric modulator | 249565628 | MK-2206 | |
208 | AKT2 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR | inhibitor | MK2206 | MK-2206 | |